- Home
- MIST vs AXR Comparison
MIST vs AXR Comparison
Compare MIST & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | AXR |
|---|---|---|
| Founded | 2003 | 1961 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.2M | 132.0M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MIST | AXR |
|---|---|---|
| Price | $1.22 | $22.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 1.0M | 9.0K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $12,831,000.00 |
| Revenue This Year | $2,915.14 | $10.12 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $17.61 |
| 52 Week High | $3.06 | $29.01 |
Technical Indicators
Market Signals| Indicator | MIST | AXR |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 33.87 |
| Support Level | $1.20 | $21.92 |
| Resistance Level | $1.42 | $22.36 |
| Average True Range (ATR) | 0.07 | 0.77 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 93.91 | 8.94 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.